
Enable Life Sciences LLC Profile last edited on: 11/29/22
CAGE: 8DEB1
UEI: DP5KPUAQYFE4
Business Identifier: Cancer immunotherapy assays using cell culture models Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
One Mifflin Place Suite 400 Harvard Square
Cambridge, MA 02138
Cambridge, MA 02138
(617) 500-3252 |
contactenablelifesciences.com |
www.enablelifesciences.com |
Location: Single
Congr. District: 05
County: Worcester
Congr. District: 05
County: Worcester
Public Profile
Managment of Enable Life Sciences define themselves as facilitating Innovation in the life sciences. The effort is to bring the innovative plans and aspirations of the firm's clients to reality through Planning, Creation and Execution. The firm, for example, will enable success through customized innovation management and R&D Project Management services, including collaborations at a global scale. Serving an array of clients including those in medical devices, pharmaceuticals, biotechnology, diagnostics, health and healthcare delivery industries The firm facilitates life sciences innovations and product development; drug and biologic formulations, drug-device combination products, medical devices; cCancer Immunotherapy cell-culture assays for immune cell activation characterization while alsotackling R&D Project Management, External Innovation, Technology and Product Development through techniques of ideation, brainstorming, prototyping and I (IP) creation along with pPre-clinical study design and execution
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NSF | $274,975 | |
Project Title: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells | ||||
2020 | 1 | NIH | $224,000 | |
Project Title: A Novel Serum Alternative for Ex-Vivo Expansion of Natural Killer Cells for Immunotherapy |
Key People / Management
Rachit Ohri -- CEO and Founder,
Michael Frid -- Consultant (Pharmaceutical Formulations)
Marc Gillig
Milind Shenvi -- Consultant (Pharmaceuticals)
Min Sheu -- Consultant (Medical Devices and Pharmaceuticals)
Gargi Sur -- Project Manager Consultant
Michael Frid -- Consultant (Pharmaceutical Formulations)
Marc Gillig
Milind Shenvi -- Consultant (Pharmaceuticals)
Min Sheu -- Consultant (Medical Devices and Pharmaceuticals)
Gargi Sur -- Project Manager Consultant
Company News
There are no news available.